Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study
Xinxin Cao(Shanghai University), Daobin Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Bing Xu(First Affiliated Hospital of Xiamen University), Shuhua Yi(Chinese Academy of Medical Sciences & Peking Union Medical College), Weili Zhao(Shanghai Jiao Tong University), Chengcheng Fu(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Renbin Zhao(Kunming University of Science and Technology), Jianda Hu(Fujian Medical University), Wei Xu(Second Military Medical University), Yongping Song(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Bin Zhang(Ningbo University), Ting Liu(Chinese PLA General Hospital), Wei Yang(China Medical University), Guohui Cui(Union Hospital), Jie Jin(Beijing Institute of Technology), Ya‐Min Tian(University of Oxford), Dengju Li(Tongji Hospital)
Cited by 43
Related Papers
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
|Blood|2020|397
Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia
|EBioMedicine|2016|345
Targeting CD47 for cancer immunotherapy
|Journal of Hematology & Oncology|2021|342
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256